Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 859-861    DOI: 10.12892/ejgo4875.2019
Case Report Previous articles | Next articles
Dysgerminoma of the ovary in an adolescent girl associated with a high serum β-human chorionic gonadotropin (β-hCG) level
A.M. Sindiani1, *(), M.S. Alorjani2, B.K. Aldaraiseh2
1Department of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and University, Irbid, Jordan
2Department of Pathology, King Abdullah University Hospital & Jordan University of Science and Technology, Irbid, Jordan
Download:  PDF(3105KB)  ( 147 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

A 14-year-old girl presented with lower abdominal pain and distension, persisting for three months. Pelvic-abdominal imaging showed a well-defined heterogeneous mass arising from the pelvis, measuring 18×10.5×23 centimetres and contained cystic degenerations. Serum tumour markers, including a beta-sub-unit of human chorionic gonadotropin (β-hCG) and lactate dehydrogenase (LDH), were highly elevated. During a laparotomy, a large right ovarian mass, measuring 20×25 centimetres and weighing more than 1,500 grams with enlarged pelvic and para-aortic lymph nodes, was discovered. A unilateral right salpingo-oophorectomy, an infracolic omentectomy, an ipsilateral lymphadenectomy and an appendectomy were then performed. Histopathologic examination revealed that the dysgerminoma FIGO Stage was IIIC. Immunohistochemical stainings were positive for placental alkaline phosphatase (PALP) and CD117. The patient received four cycles of chemotherapy and had a strict follow-up of computed tomography (CT) scans, providing images with an analysis of tumour markers over the following two years. All the changes were restored to within normal limits without any evidence of recurrence.

Key words:  Immunohistochemistry      Ovarian dysgerminoma      Tumour markers      Beta-sub-unit of human chorionic gonadotropin (β-hCG)     
Published:  10 October 2019     
*Corresponding Author(s):  A.M. SINDIANI     E-mail:  amsindiani0@just.edu.jo

Cite this article: 

A.M. Sindiani, M.S. Alorjani, B.K. Aldaraiseh. Dysgerminoma of the ovary in an adolescent girl associated with a high serum β-human chorionic gonadotropin (β-hCG) level. European Journal of Gynaecological Oncology, 2019, 40(5): 859-861.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4875.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/859

[1] Jaudah Al-Maghrabi, Haneen Al-Maghrabi. SIRT1 is overexpressed in endometrial adenocarcinoma: a tissue microarray analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 699-704.
[2] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[3] Hyang Sook Jeong, Yuki Gen, Hui Ryun Joo, Ji Geun Yoo, Seung Geun Yeo, Dong Choon Park. Mesonephric-like carcinoma of the uterine corpus: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 664-667.
[4] Soo-Young Lee, Dae-Hyung Lee. Perivascular epithelioid cell tumor arising in the left parametrium: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 657-660.
[5] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[6] Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.
[7] M.H. Hajeer, A. Al Khader, N.A. Shahin, M.S. Bata. Negative p53 expression and negative high risk HPV in a 26-year-old lady with vulvar keratinizing squamous cell carcinoma: report of a case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 130-133.
[8] N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.
[9] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[10] H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.
[11] S. Kabukcuoglu, B. Hayit. Histopathologic features of advanced stage endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 614-618.
[12] Lan Zhong, Feng Deng, Xingsheng Shu, Zhilan Peng. P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 463-467.
[13] H. Cao, S. Yang, S. Xie, M. Xi. The association between p16INK4a and prognosis in endometrial carcinoma: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 311-317.
[14] Xiang Wang, Zhuo Deng, Lijie Wang, He Chen, Huilian Hou, Xu Li. Immunohistochemical analysis of IQGAP2 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 74-79.
[15] Weili He, Hening Zhai, Ningxia Wang. Expression of FOXA1 in breast cancer and the significance[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 97-100.
No Suggested Reading articles found!